POPULATION PHARMACOKINETIC (PPK) AND EXPOSURE-RESPONSE EVALUATION OF NIVOLUMAB WITH CHEMOTHERAPY AS FIRST LINE TREATMENT IN PATIENTS WITH GASTRIC/GASTROESOPHAGEAL JUNCTION/ESOPHAGEAL ADENOCARCINOMA (CHECKMATE-649:CM649).
CLINICAL PHARMACOLOGY & THERAPEUTICS（2022）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要